Authors

Latest:

Dr Wong on Challenges Incorporating Checkpoint Inhibitors into Curative-Intent Regimens in HNSCC

Deborah J. Wong, MD, PhD, discusses challenges incorporating checkpoint inhibitors into curative-intent approaches for patients with head and neck squamous cell carcinoma.

Sponsored by Janssen Oncology

Latest:

Bispecific Targeting CD3 and BCMA Reflect Expanding Options in Multiple Myeloma

Bispecific antibodies targeting BCMA have shown efficacy in relapsed refractory multiple myeloma, including bispecifics targeting BCMA x CD3.

Ahmet Sezer, MD

Latest:

Dr. Sezer on the FDA Approval of Cemiplimab in Frontline Advanced NSCLC With High PD-L1 Expression

Ahmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, discusses the FDA approval of cemiplimab-rwlc (Libtayo) as frontline treatment for patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression.

Shivaani Kummar, MBBS, FACP

Latest:

Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors

Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.

Salvatore Siena, MD

Latest:

Dr. Siena on the Rationale for the DESTINY-CRC01 in Metastatic CRC

Salvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.

Vincent Ma, MD

Latest:

18F-FDG PET/CT May Serve as Early Interval Response Assessment Tool in Patients Receiving Combinatorial ICI Therapy

Functional imaging information from 18F-FDG PET can complement data from anatomic imaging studies from CT and MRI to predict response to ICI therapy.

Ulka Nitin Vaishampayan, MBBS

Latest:

Dr Vaishampayan on the Rationale For the SWOG-1931/PROBE Trial in Advanced RCC

Ulka Nitin Vaishampayan, MBBS, discusses the rationale for conducting the phase 3 SWOG 1931 trial in patients with advanced renal cell carcinoma.

Phillip Palmbos, MD, PhD

Latest:

Dr. Palmbos on the Utilization of Nivolumab Following Cystectomy in Muscle-Invasive Bladder Cancer

Phillip Palmbos, MD, PhD, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder cancer.

Sandip P. Patel, MD, UC San Diego Health

Latest:

Second-Line Treatment of SCLC

Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.

Ignacio Duran, MD, PhD

Latest:

Treatment Options After Frontline Maintenance Therapy in mUC

Following frontline maintenance therapy in metastatic urothelial carcinoma, Ignacio Duran, MD, PhD, considers optimal second-line treatment options.

Mohammed M. Milhem, MBBS

Latest:

Dr. Milhem on the Utility of RP1 in Solid Tumors

Mohammed Milhem, MBBS, MBBS, discusses the utility of vusolimogeneoderparepvec in solid tumors.

John Zalcberg, PhD, OAM

Latest:

Dr. Zalcberg on the Rationale for Dose Escalation With Ripretinib in Advanced GIST

John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Ronda S. Henry-Tillman, MD

Latest:

Comprehensive Treatment Advances Care for Patients With Early-Stage Breast Cancer

Advances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.

Pramit Khetrapal, MD

Latest:

Dr. Khetrapal on Intracorporeal Robotic vs Open Cystectomy in MIBC

Pramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.

Toby Campbell, MD, MSCI

Latest:

Palliative Care Builds Bridges in Oncology Practice

Toby Campbell, MD, MSCI, discusses the nuances of palliative care in oncology.

Sarah Wolfson, PhD

Latest:

The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality

One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.

Varun Monga, MD

Latest:

Dr Monga on the Background of Investigating PRT811 in Glioma and Melanoma

Varun Monga, MD, discusses the background for investigating the protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 in a phase 1 study in patients with recurrent high-grade glioma or uveal melanoma, as well as the agent’s mechanism of action.

Katsunori Asai, MD, PhD

Latest:

Dr Asai on Final Results From a Phase 1/2 Trial of Tirabrutinib in R/R PCNSL

Katsunori Asai, MD, PhD, Department of Neurosurgery, Osaka International Cancer Institute, Osaka, Japan, discusses the use of tirabrutinib in patients with relapsed/refractory primary central nervous system lymphoma according to a phase 1/2 study (JapicCTI-173646).

Chunhui Fang, MD

Alicia K. Morgans, MD, MPH, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Latest:

Advances in Nonmetastatic CRPC

An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.